Alan F. Schatzberg, MD

In Memoriam

In Memoriam: Terence A. Ketter, MD

August 18, 2025

Eminent bipolar disorder researcher and clinician Terence A. Ketter, MD, is remembered.

Alan F. Schatzberg, Robert Post

Original Research

Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine

September 4, 2024

This study suggests that cognitive function does not moderate depression outcomes in vortioxetine, with results comparable to other antidepressants.

Joshua T. Jordan, Li Shen, Nicholas J. Cooper, et al

Original Research

Antidepressant Side Effects and Panic

April 26, 2017

Do depressed patients with comorbid panic disorder have antidepressant treatment side effect profiles that differ from those of patients without panic disorder? Check out this article to review the...

Rachel Manber, Alan F. Schatzberg, Madhukar H. Trivedi, et al

Academic Highlights

Overview of Vortioxetine (Brintellix)

December 24, 2014

Understand what is Vortioxetine (Brintellix), an antidepressant for major depressive disorder and treatment-resistant depression.

Alan F. Schatzberg, Michael E. Thase, George I. Papakostas, et al

Original Research

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

August 15, 2007

David L. Dunner, Susan G. Kornstein, Alan F. Schatzberg, et al

Article

Safety and Tolerability of Antidepressants: Weighing the Impact on Treatment Decisions

July 16, 2007

Alan F. Schatzberg

Original Research

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

July 16, 2007

David L. Dunner, Susan G. Kornstein, Alan F. Schatzberg, et al

Original Research

Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study

April 16, 2007

David L. Dunner, David Michelson, Lenard A. Adler, et al

Academic Highlights

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

February 15, 2007

Alan F. Schatzberg, Michael E. Thase, Elliott Richelson, et al

Article

Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research.

April 15, 2006

Maurizio Fava, Alan F. Schatzberg, Richard C. Shelton, et al

Article

Employing Pharmacologic Treatment of Bipolar Disorder to Greatest Effect

November 15, 2004

Alan F. Schatzberg

Article

Recognizing and Treating the Physical Symptoms of Depression in Primary Care

August 13, 2004

Alan F. Schatzberg, Pedro L. Delgado, Bruce A. Arnow, et al

In Memoriam: Terence A. Ketter, MD

Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine

Antidepressant Side Effects and Panic

Overview of Vortioxetine (Brintellix)

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Safety and Tolerability of Antidepressants: Weighing the Impact on Treatment Decisions

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research.

Employing Pharmacologic Treatment of Bipolar Disorder to Greatest Effect

Recognizing and Treating the Physical Symptoms of Depression in Primary Care

ELSEWHERE:

FOLLOW US:

Alan F. Schatzberg, MD

In Memoriam: Terence A. Ketter, MD

Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine

Antidepressant Side Effects and Panic

Overview of Vortioxetine (Brintellix)

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Safety and Tolerability of Antidepressants: Weighing the Impact on Treatment Decisions

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Addition of Atomoxetine for Depression Incompletely Responsive to Sertraline: A Randomized, Double-Blind, Placebo-Controlled Study

Transcranial Magnetic Stimulation: Potential New Treatment for Resistant Depression.

Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research.

Employing Pharmacologic Treatment of Bipolar Disorder to Greatest Effect

Recognizing and Treating the Physical Symptoms of Depression in Primary Care

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles